JO3503B1 - مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها - Google Patents

مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها

Info

Publication number
JO3503B1
JO3503B1 JOP/2015/0271A JOP20150271A JO3503B1 JO 3503 B1 JO3503 B1 JO 3503B1 JO P20150271 A JOP20150271 A JO P20150271A JO 3503 B1 JO3503 B1 JO 3503B1
Authority
JO
Jordan
Prior art keywords
hydroxyalkyl
phenyltriazole derivatives
substituted
compounds
treatment
Prior art date
Application number
JOP/2015/0271A
Other languages
English (en)
Inventor
Mondritzki Thomas
Sonja Vollmer Dr
Peter Kolkhof Dr
Florian K?Lling Dr
Dieter Lang Dr
Su?Meier Frank
Carsten Schmeck Dr
Klemens Lustig Dr
Nils Griebenow Dr
Pierre Wasnaire Dr
Michael Gerisch Dr
Elisabeth Pook Dr
Axel Kretschmer Dr
Hartmut Beck Dr
Anna Engelen Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3503B1 publication Critical patent/JO3503B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole جديدة، بعمليات لتحضير هذه المركبات، بتركيبات دوائية تحتوي على هذه المركبات، وباستخدام هذه المركبات أو التركيبات لمعالجة و/أو منع أمراض، تحديداً لمعالجة و/أو منع أمراض قلبية وعائية وكلوية.
JOP/2015/0271A 2014-11-03 2015-11-02 مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها JO3503B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14191491 2014-11-03

Publications (1)

Publication Number Publication Date
JO3503B1 true JO3503B1 (ar) 2020-07-05

Family

ID=51897095

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0271A JO3503B1 (ar) 2014-11-03 2015-11-02 مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها

Country Status (40)

Country Link
US (2) US20170313665A1 (ar)
EP (1) EP3215498B1 (ar)
JP (1) JP6623220B2 (ar)
KR (1) KR20170081178A (ar)
CN (1) CN107074783B (ar)
AR (1) AR102487A1 (ar)
AU (1) AU2015342017B2 (ar)
BR (1) BR112017009204A2 (ar)
CA (1) CA2966256A1 (ar)
CL (1) CL2017001087A1 (ar)
CO (1) CO2017004471A2 (ar)
CU (1) CU24462B1 (ar)
CY (1) CY1120941T1 (ar)
DK (1) DK3215498T3 (ar)
DO (1) DOP2017000109A (ar)
EA (1) EA032137B1 (ar)
EC (1) ECSP17026733A (ar)
ES (1) ES2697902T3 (ar)
GT (1) GT201700094A (ar)
HR (1) HRP20181742T1 (ar)
HU (1) HUE040696T2 (ar)
IL (1) IL251354B (ar)
JO (1) JO3503B1 (ar)
LT (1) LT3215498T (ar)
MA (1) MA40893B1 (ar)
MX (1) MX2017005479A (ar)
MY (1) MY186908A (ar)
PE (1) PE20170945A1 (ar)
PH (1) PH12017500802A1 (ar)
PL (1) PL3215498T3 (ar)
PT (1) PT3215498T (ar)
RS (1) RS58049B1 (ar)
SA (1) SA517381429B1 (ar)
SG (1) SG11201703199UA (ar)
SI (1) SI3215498T1 (ar)
SV (1) SV2017005426A (ar)
TW (1) TWI694072B (ar)
UY (1) UY36383A (ar)
WO (1) WO2016071212A1 (ar)
ZA (1) ZA201703802B (ar)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187466B2 (en) 2010-02-27 2015-11-17 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
CR20170566A (es) 2015-06-09 2018-03-20 Bayer Pharma AG Moduladores alostéricos positivos del receptor muscarínico m2
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CA3022755A1 (en) * 2016-05-03 2017-11-09 Carsten Schmeck Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US20190119251A1 (en) 2016-05-03 2019-04-25 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
EP3452470B1 (en) 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Amide-substituted phenyltriazole derivatives and uses thereof
CN109071500B (zh) * 2016-05-03 2021-05-18 拜耳制药股份公司 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法
WO2017191112A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
US10519154B2 (en) 2016-07-11 2019-12-31 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3529244A1 (en) 2016-10-20 2019-08-28 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
WO2018149929A1 (en) * 2017-02-16 2018-08-23 Bayer Pharma Aktiengesellschaft Combination of reporter gene assays and transcriptional analysis
MA50438B1 (fr) 2017-10-24 2022-03-31 Bayer Pharma AG Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci
EP3700898A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081307A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
KR20200076686A (ko) 2017-10-24 2020-06-29 바이엘 악티엔게젤샤프트 치환된 이미다조피리딘 아미드 및 그의 용도
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
CA3079771A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019141575A1 (de) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
AU2019269047A1 (en) 2018-05-15 2020-11-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3793559A1 (en) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
CN110082451B (zh) * 2019-05-23 2021-12-24 南京趣酶生物科技有限公司 一种2-氯-1-(6-氟-色满-2-)乙醇手性醇中间体制备过程的sfc检测方法
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
US20230201174A1 (en) 2020-04-22 2023-06-29 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP3900722A1 (en) 2020-04-22 2021-10-27 Bayer AG Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
CN115175681A (zh) 2020-12-10 2022-10-11 拜耳公司 sGC活化剂用于治疗眼科疾病的用途
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CA3204495A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CA3204595A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
CN114835688A (zh) * 2021-02-02 2022-08-02 深圳信立泰药业股份有限公司 一种取代的4-芳基咪唑-2-酮衍生物及其制备方法和医药用途
WO2022214206A1 (en) 2021-04-08 2022-10-13 Bayer Aktiengesellschaft Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
TW202412753A (zh) 2022-06-09 2024-04-01 德商拜耳廠股份有限公司 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1992020662A1 (en) 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
CA2338304A1 (en) 1998-07-24 2000-02-03 Bayer Aktiengesellschaft Substituted benzoylcyclohexandiones
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
WO2000059510A1 (en) 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
WO2005006892A2 (en) 2003-06-27 2005-01-27 Berglin Corporation Of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
CA2551038C (en) * 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
BRPI0508532A (pt) 2004-03-08 2007-08-07 Wyeth Corp moduladores do canal de ìon
WO2005097112A2 (en) 2004-03-08 2005-10-20 Wyeth Ion channel modulators
EP1742932A1 (en) 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
MX2009011541A (es) * 2007-04-26 2009-11-09 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas nk3.
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US9187466B2 (en) * 2010-02-27 2015-11-17 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US9604976B2 (en) 2012-03-22 2017-03-28 Spero Gyrase, Inc. Antibacterial compounds
JP2016532721A (ja) * 2013-10-07 2016-10-20 バイエル ファーマ アクチエンゲゼルシャフト 環状チエノウラシルカルボキサミドおよびその使用

Also Published As

Publication number Publication date
MA40893A (fr) 2017-09-13
PL3215498T3 (pl) 2019-02-28
UY36383A (es) 2016-06-01
DK3215498T3 (en) 2018-12-10
EA032137B1 (ru) 2019-04-30
WO2016071212A1 (en) 2016-05-12
CL2017001087A1 (es) 2018-01-26
KR20170081178A (ko) 2017-07-11
IL251354B (en) 2020-08-31
MY186908A (en) 2021-08-26
CY1120941T1 (el) 2019-12-11
TWI694072B (zh) 2020-05-21
HRP20181742T1 (hr) 2018-12-28
ES2697902T3 (es) 2019-01-29
MA40893B1 (fr) 2018-11-30
LT3215498T (lt) 2018-11-12
CA2966256A1 (en) 2016-05-12
MX2017005479A (es) 2017-07-04
ECSP17026733A (es) 2017-05-31
EP3215498A1 (en) 2017-09-13
AU2015342017B2 (en) 2020-02-06
GT201700094A (es) 2019-07-29
HUE040696T2 (hu) 2019-03-28
CN107074783A (zh) 2017-08-18
CO2017004471A2 (es) 2017-07-19
SG11201703199UA (en) 2017-05-30
EP3215498B1 (en) 2018-08-22
PE20170945A1 (es) 2017-07-13
TW201629044A (zh) 2016-08-16
CU24462B1 (es) 2020-01-03
JP2017533233A (ja) 2017-11-09
CU20170057A7 (es) 2017-10-05
PT3215498T (pt) 2018-11-28
SI3215498T1 (sl) 2018-11-30
AR102487A1 (es) 2017-03-01
EA201790951A1 (ru) 2017-09-29
CN107074783B (zh) 2020-06-05
US20170313665A1 (en) 2017-11-02
RS58049B1 (sr) 2019-02-28
ZA201703802B (en) 2019-12-18
DOP2017000109A (es) 2017-07-31
US20160122325A1 (en) 2016-05-05
AU2015342017A1 (en) 2017-04-27
IL251354A0 (en) 2017-05-29
PH12017500802B1 (en) 2017-10-02
BR112017009204A2 (pt) 2018-07-03
SV2017005426A (es) 2017-07-04
PH12017500802A1 (en) 2017-10-02
US9771352B2 (en) 2017-09-26
JP6623220B2 (ja) 2019-12-18
SA517381429B1 (ar) 2021-04-01

Similar Documents

Publication Publication Date Title
JO3503B1 (ar) مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12019500056A1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MY193728A (en) Muscarinic receptor agonists
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
GEP20186910B (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
SI3057580T1 (sl) Farmacevtske dozirne oblike, ki vsebujejo natrijev 1-(6-(morfolin-4-il)pirimidin-4-il)-4-(1H-1,2,3-triazol-1-il)-1H- pirazol-5-olat
MX2016016381A (es) Derivados de tetrahidrotriazolopirimidina, composiciones farmaceuticas que contienen los mismos y usos.
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.